La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
4D Molecular Therapeutics Gestione
Gestione criteri di controllo 2/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
David Kirn
Amministratore delegato
US$10.3m
Compenso totale
| Percentuale dello stipendio del CEO | 5.8% |
| Mandato del CEO | 11yrs |
| Proprietà del CEO | 3.2% |
| Durata media del management | 2.9yrs |
| Durata media del Consiglio di amministrazione | 3.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans
Aug 10
4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data
Jul 194D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution
Apr 294D Molecular Therapeutics Advances Wet AMD Treatment Paradigm
Feb 064D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024
Jan 254D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 12We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Nov 08Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
May 08We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Sep 294D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M
Aug 11Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
Jun 11We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely
Aug 06Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$110m |
| Mar 31 2024 | n/a | n/a | -US$105m |
| Dec 31 2023 | US$10m | US$597k | -US$101m |
| Sep 30 2023 | n/a | n/a | -US$96m |
| Jun 30 2023 | n/a | n/a | -US$111m |
| Mar 31 2023 | n/a | n/a | -US$110m |
| Dec 31 2022 | US$3m | US$586k | -US$107m |
| Sep 30 2022 | n/a | n/a | -US$105m |
| Jun 30 2022 | n/a | n/a | -US$102m |
| Mar 31 2022 | n/a | n/a | -US$81m |
| Dec 31 2021 | US$5m | US$570k | -US$71m |
| Sep 30 2021 | n/a | n/a | -US$67m |
| Jun 30 2021 | n/a | n/a | -US$52m |
| Mar 31 2021 | n/a | n/a | -US$60m |
| Dec 31 2020 | US$702k | US$451k | -US$57m |
| Sep 30 2020 | n/a | n/a | -US$52m |
| Jun 30 2020 | n/a | n/a | -US$61m |
| Mar 31 2020 | n/a | n/a | -US$54m |
| Dec 31 2019 | US$554k | US$430k | -US$49m |
| Sep 30 2019 | n/a | n/a | -US$35m |
| Jun 30 2019 | n/a | n/a | -US$21m |
| Mar 31 2019 | n/a | n/a | -US$15m |
| Dec 31 2018 | US$546k | US$396k | -US$10m |
Compensazione vs Mercato: La retribuzione totale di David ($USD 10.29M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 3.30M ).
Compensazione vs guadagni: La retribuzione di David è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
David Kirn (61 yo)
11yrs
Mandato
US$10,286,808
Compensazione
Dr. David H. Kirn, M.D., serves as Director at Coagulant Therapeutics, Inc He co-founded 4D Molecular Therapeutics, Inc. in 2013 and has been its Chief Executive Officer since September 12, 2013. Dr. Kirn...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | 4.1yrs | US$581.44k | 0.19% $ 1.1m | |
| Co-Founder | 11yrs | US$10.29m | 3.19% $ 18.0m | |
| President & COO | 4.6yrs | US$4.54m | 0.011% $ 64.3k | |
| Chief Scientific Officer | less than a year | US$488.91k | Nessun dato | |
| Chief Medical Officer | 1.9yrs | US$3.96m | 0.0020% $ 11.3k | |
| Co-Founder & Chief of Staff | 11.7yrs | US$2.70m | Nessun dato | |
| Chief Financial & Business Officer | less than a year | Nessun dato | Nessun dato | |
| Chief Legal Officer & Corporate Secretary | 3yrs | Nessun dato | 0.013% $ 73.4k | |
| Chief Development Officer | 2.8yrs | Nessun dato | Nessun dato | |
| Senior VP & Therapeutic Area Head of Pulmonology | no data | Nessun dato | Nessun dato | |
| Chief Commercial Officer | no data | Nessun dato | Nessun dato | |
| Controller | 8.1yrs | Nessun dato | Nessun dato |
2.9yrs
Durata media
61yo
Età media
Gestione esperta: Il team dirigenziale di FDMT è considerato esperto (durata media dell'incarico 2.9 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | 4.1yrs | US$581.44k | 0.19% $ 1.1m | |
| Co-Founder | 11yrs | US$10.29m | 3.19% $ 18.0m | |
| Independent Director | 8.8yrs | US$352.62k | 0.062% $ 350.4k | |
| Independent Director | 4.2yrs | US$352.62k | 0% $ 0 | |
| Member of Scientific Advisory Board | less than a year | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | less than a year | Nessun dato | Nessun dato | |
| Independent Director | 5.5yrs | US$352.62k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$345.12k | 0% $ 0 | |
| Member of Scientific Advisory Board | less than a year | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | less than a year | Nessun dato | Nessun dato | |
| Independent Director | 3.8yrs | US$340.12k | 0% $ 0 | |
| Chair of Ophthalmology Advisory Board | less than a year | Nessun dato | Nessun dato |
3.8yrs
Durata media
62yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di FDMT sono considerati esperti (durata media dell'incarico 3.8 anni).